(7-苯基蝶啶-4-基)胺 | 73384-11-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 蝶啶及其衍生物
• 中文名称: (7-苯基蝶啶-4-基)胺
• 英文名称: 4-Amino-7-phenylpteridine
• 英文别名: 4-amino-7-phenyl-pteridine；4-Pteridinamine, 7-phenyl-；7-phenylpteridin-4-amine
• CAS: 73384-11-9
• 化学式: C₁₂H₉N₅
• 分子量: 223.237
• InChiKey: YZCLSEIRDPNKJP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  77.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (7-苯基蝶啶-4-基)胺 在 盐酸 作用下， 反应 0.25h， 以72%的产率得到7-苯基喋啶-4-醇
  参考文献：
  名称：

  Sladowska, H.; De Meester, J. W. G.; Plas, H. C. van der, Journal of Heterocyclic Chemistry, 1986, vol. 23, p. 477 - 480

  摘要：

  DOI：
• 作为产物：
  描述：

  7-苯基蝶啶 在 potassium permanganate 、 氨 作用下， 反应 4.0h， 以90%的产率得到(7-苯基蝶啶-4-基)胺
  参考文献：
  名称：

  Sladowska, H.; De Meester, J. W. G.; Plas, H. C. van der, Journal of Heterocyclic Chemistry, 1986, vol. 23, p. 477 - 480

  摘要：

  DOI：

文献信息

• Diuretics
  申请人：Abbott Laboratories

  公开号：US04187307A1

  公开（公告）日：1980-02-05

  Specific 4-amino pteridines carrying particular phenyl substituents in the 7-position and no substituents in the 2-position have been found to be excellent nonkaliuretic diuretics at doses of 30 to 500 mg/kg in warm-blooded animals.

  在7位带有特定苯基取代基且在2位没有取代基的特定4-氨基喹噁啉类化合物已被发现在温血动物中以30至500毫克/千克的剂量下表现出优异的非钾利尿作用。
• Vasculostatic agents and methods of use thereof
  申请人：Targegen, Inc.

  公开号：EP2039683A2

  公开（公告）日：2009-03-25

  Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as retinopathies or macular degeneration or other vitreoretinal diseases, inflammatory diseases, vascular leakage syndrome, edema, transplant rejection, adult/acute respiratory distress syndrome (ARDS), and the like.

  本发明提供的组合物和方法可用于治疗与血管稳态受损相关的疾病。发明的方法和组合物可用于治疗多种疾病，例如中风、心肌梗塞、癌症、缺血/再灌注损伤、类风湿性关节炎等自身免疫性疾病、视网膜病变或黄斑变性等眼部疾病或其他玻璃体视网膜疾病、炎症性疾病、血管渗漏综合征、水肿、移植排斥反应、成人/急性呼吸窘迫综合征（ARDS）等。
• Discovery of 3,3‘-(2,4-Diaminopteridine-6,7-diyl)diphenol as an Isozyme-Selective Inhibitor of PI3K for the Treatment of Ischemia Reperfusion Injury Associated with Myocardial Infarction
  作者：Moorthy S. S. Palanki、Elena Dneprovskaia、John Doukas、Richard M. Fine、John Hood、Xinshan Kang、Dan Lohse、Michael Martin、Glenn Noronha、Richard M. Soll、Wolfgang Wrasidlo、Shiyin Yee、Hong Zhu

  DOI：10.1021/jm051056c

  日期：2007.9.1

  In studies aimed toward identifying effective and safe inhibitors of kinase signaling cascades that underlie ischemia/reperfusion (I/R) injury, we synthesized a series of pteridines and pyridopyrazines. The design strategy was inspired by the examination of naturally occurring PI3K inhibitors such as wortmannin and quercetin, and building a pharmacophore-based model used for optimization. Structural modifications led to hybrid molecules which incorporated aminopyrimidine and aminopyridine moieties with ATP mimetic characteristics into the pharmacophore motifs to modulate kinase affinity and selectivity. Elaborations involving substitutions of the 2 and 4 positions of the pyrimidine or pyridine ring and the 6 and 7 positions of the central pyrazine ring resulted in in vivo activity profiles which identified potent inhibitors of vascular endothelial growth factor (VEGF) induced vascular leakage. Pathway analysis identified a diaminopteridine-diphenol as a potent and selective phosphatidylinositol-3-kinase (PI3K) inhibitor. The structure -activity relationship studies of various analogues of diaminopteridine-diphenol-based on biochemical assays resulted in potent inhibitors of PI3K.
• Discovery of 4-Amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin- 3-yl)pyrido[2,3-<i>d</i>]pyrimidine, an Orally Active, Non-Nucleoside Adenosine Kinase Inhibitor
  作者：Chih-Hung Lee、Meiqun Jiang、Marlon Cowart、Greg Gfesser、Richard Perner、Ki Hwan Kim、Yu Gui Gu、Michael Williams、Michael F. Jarvis、Elizabeth A. Kowaluk、Andrew O. Stewart、Shripad S. Bhagwat

  DOI：10.1021/jm000314x

  日期：2001.6.1

  Adenosine (ADO) is an endogenous homeostatic inhibitory neuromodulator that reduces cellular excitability at sites of tissue injury and inflammation, inhibition of adenosine kinase (AK), the primary metabolic enzyme for ADO, selectively increases ADO concentrations at sites of tissue trauma and enhances the analgesic and antiinflammatory actions of ADO. Optimization of the high-throughput screening lead, 4-amino-7-aryl-substituted pteridine (5) (AK IC50 = 440 nM), led to the identification of compound 21 (4-amino-5-(3-bromophenyl)-7-(6-morpholino- pyridin-3-yl)pyrido [2,3-d]pyrimidine, ABT-702), a novel, potent (AK IC50 = 1.7 nM) non-nucleoside AK inhibitor with oral. activity in animal models of pain and inflammation.
• US4187307A
  申请人：——

  公开号：US4187307A

  公开（公告）日：1980-02-05